The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PROF | +5.06% | -66.41% | -19.6% | -27% |
| S&P | +18.89% | +78.8% | +12.32% | +225% |
Profound Medical Corp. engages in developing, manufacturing, and marketing of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. Its platforms offer clinicians and patients incision-free alternatives to current standards of care, which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, Canada.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $5.29M | 86.8% |
| Gross Profit | $3.93M | 119.9% |
| Gross Margin | 74.32% | 11.2% |
| Market Cap | $146.96M | -24.6% |
| Market Cap / Employee | $1.03M | 0.0% |
| Employees | 142 | 0.0% |
| Net Income | -$7,977.00K | 14.8% |
| EBITDA | -$8,766.00K | 0.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $24.83M | -8.5% |
| Accounts Receivable | $7.31M | 12.9% |
| Inventory | 8.3 | 29.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $4.76M | 93.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -93.45% | -24.6% |
| Return On Invested Capital | -45.71% | 5.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9,711.62K | -42.1% |
| Operating Free Cash Flow | -$9,711.62K | -42.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.96 | 2.89 | 3.49 | 3.74 | -24.63% |
| Price to Sales | 18.12 | 14.45 | 15.07 | 10.29 | -55.17% |
| Price to Tangible Book Value | 6.03 | 2.91 | 3.51 | 3.76 | -25.01% |
| Enterprise Value to EBITDA | -17.70 | -11.80 | -10.83 | -14.49 | -27.02% |
| Return on Equity | -60.7% | -66.4% | -104.2% | -125.2% | 36.44% |
| Total Debt | $5.12M | $4.88M | $4.81M | $4.76M | -22.70% |
No podcast episodes available.
PROF earnings call for the period ending June 30, 2022.
PROF earnings call for the period ending March 31, 2022.
PROF earnings call for the period ending December 31, 2021.
PROF earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
